Preclinical evaluation of HBY 097, a new nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 replication.

@article{Kleim1995PreclinicalEO,
  title={Preclinical evaluation of HBY 097, a new nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 replication.},
  author={J P Kleim and Rudolf Dr Bender and R. Kirsch and Christoph Meichsner and A Paessens and Manfred Roesner and Helga Prof Ruebsamen-Waigmann and Rolf Kaiser and Maria Wichers and Karl Eduard Schneweis},
  journal={Antimicrobial agents and chemotherapy},
  year={1995},
  volume={39 10},
  pages={
          2253-7
        }
}
HBY 097 [(S)-4-isopropoxycarbonyl-6-methoxy-3-(methylthiomethyl)-3, 4-dihydroquinoxaline-2(1H)-thione] was selected from a series of quinoxalines as a nonnucleoside inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (NNRTI). HBY 097 was shown to be a highly potent inhibitor of HIV-1 induced cell killing and HIV-1 replication in a variety of human cell lines as well as in fresh human peripheral blood lymphocytes and macrophages. The compound was also active against a… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 12 CITATIONS

Non-nucleoside reverse transcriptase inhibitors: the NNRTI boom.

  • Antiviral chemistry & chemotherapy
  • 1999
VIEW 4 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED